Enhanced Oral Bioavailability of Poorly Absorbed Drugs. I. Screening of Absorption Carrier for the Ceftriaxone Complex

Journal of Pharmaceutical Sciences

Volumn 93, Issue 3, 2004, Pages 612-620

  Cho, Seong Wan ^a   Lee, Jeoung Soo ^a   Choi, Seung Ho ^b  

^a UNIVERSITY OF UTAH   (United States)

^b MC Technologies   (United States)

Author keywords

Bioavailability; Ceftriaxone complex; Oral drug delivery

Indexed keywords

CAPMUL MCM C10; CARRAGEENAN; CEFTRIAXONE; DRUG CARRIER; GELUCIRE; GELUCIRE 44 14; GLYCYRRHIZIC ACID; OCTANOIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG SAFETY; DRUG SCREENING; GASTROINTESTINAL ABSORPTION; MEMBRANE STRUCTURE; NONHUMAN; RAT; SCANNING ELECTRON MICROSCOPY; SURFACE PROPERTY;

EID: 1542515212     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.10563     Document Type: Article

References (27)

1. Choi SH, Lee JS. 2001 Jun 19. Complexes to improve oral absorption of poorly absorbable antibiotics. US patent 6,248,360 B1.
2. Sekine M, Terashima H, Sasahara K, Nishimura K, Okada R, Awazu S. 1985. Improvement of bioavailability of poorly absorbed drugs. II. Effect of medium chain glyceride base on the intestinal absorption of cefmetazole sodium in rats and dogs. J Pharmacobiodyn 8:286-295.
3. Sutton SC, Lecluyse EL, Engle K, Pipkin JD, Fix JA. 1993. Enhanced bioavailability of cefoxitin using palmitoylcarnitine. II. Use of directly compressed tablet formulations in the rat and dog. Pharm Res 10(10):1516-1520.
4. Swenson ES, Milisen WB, Curatolo W. 1994. Intestinal permeability enhancement: Efficacy, acute local toxicity, and reversibility. Pharm Res 11(8):1132-1142.
5. Lindmark T, Söderholm JD, Olaison G, Alván G, Ocklind G, Artursson P. 1997. Mechanism of absorption enhancement in humans after rectal administration of ampicillin in suppositories containing sodium caprate. Pharm Res 14(7):930-935.
6. Beam TR, Jr. 1985. Ceftriaxone: A beta-lactamase-stable, broad-spectrum cephalosporin with an extended half-life. Pharmacotherapy 5(5):237-253.
7. Yuk JH, Nightingale CH, Quintiliani R. 1989. Clinical pharmacokinetics of ceftriaxone. Clin Pharmcokinet 17(4):223-235.
8. Patel IH, Kaplan SA. 1984. Pharmacokinetic profile of ceftriaxone in man. Am J Med 77:17-25.
9. Scully BE, Fu KP, Neu HC. 1984. Pharmacokinetics of ceftriaxone after intravenous infusion and intramuscular injection. Am J Med 77:112-116.
10. Hakim L, Bourne DWA, Triggs EJ. 1989. Disposition of ceftriaxone in rat: Application of a pharmacokinetic-protein binding model and comparison with cefotaxime. Xenobiotica 19(8):815-822.
11. Dantzig AH. 1997. Oral absorption of β-lactams by intestinal peptide transport protein. Adv Drug Deliv Rev 23:63-76.
12. Yang CY, Dantzig AH, Pidgeon C. 1999. Intestinal peptide transport systems and oral drug availability. Pharm Res 16(9):1331-1343.
13. Serajuddin AT, Sheen PC, Mufson D, Bernstein DF, Augustine MA. 1988. Effect of vehicle amphiphilicity on the dissolution and bioavailability of a poorly water-soluble drug from solid dispersions. J Pharm Sci 77(5):414-417.
14. Hauss DJ, Fogal SE, Ficorilli JV, Price CA, Roy T, Jayaraj AA, Keirns JJ. 1998. Lipid-based delivery systems for improving the bioavailability and lymphatic transport of a poorly water-soluble LTB4 inhibitor. J Pharm Sci 87(2):164-169.
15. Danaka M, Takahashi M, Kuwahara E, Kovama O, Ohkubu K, Yotsuyanagi T. 1992. Effect of glycyrrhizinate on dissolution behavior and rectal absorption of amphotericin B in rabbits. Chem Pharm Bull 40:1559-1562.
16. Wang Z, Kurosaki Y, Nakayama T, Kimura T. 1994. Mechanism of gastrointestinal absorption of glycyrrhizin in rats. Biol Pharm Bull 17(10):1399-1403.
17. Beskid G, Unowsky J, Behl CR, Siebelist J. 1988. Enteral, oral, and rectal absorption of ceftriaxone using glyceride enhancers. Chemotherapy 34:77-84.
18. Tomita M, Hayashi M, Horie T, Ishizawa T, Awazu S. 1988. Enhancement of colonic drug absorption by the transcellular permeation route. Pharm Res 5(12):786-789.
19. Aungst BJ. 2000. Intestinal permeation enhancers. J Pharm Sci 89(4):429-442.
20. Lindmark T, Kimura Y, Artursson P. 1998. Absorption enhancement through intracellular regulation of tight junction permeability by medium chain fatty acids in caco-2 cells. J Pharmacol Exp Ther 269:813-822.
21. Hakim L, Bourne DWA. 1988. High-performance liquid chromatographic assay of cefotaxime, desacetylcefotaxime and ceftriaxone in rat plasma. J Chromatogr 424(1):111-117.
22. Dressman JB, Reppas C. 2000. In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs. Eur J Pharm Sci 11(Suppl 2):S73-S80.
23. Yeh PY, Smith PL, Ellens H. 1994. Effect of medium-chain glycerides on physiological properties of rabbit intestinal epithelium in vitro. Pharm Res 11(8):1148-1154.
24. Sekine M, Terashima H, Sasahara K, Nishimura T, Okada R, Awazu S. 1984. Improvement of bioavailability of poorly absorbed drugs. I. Effect of medium chain glyceride base on the rectal absorption of cefmetazole sodium in rats. J Pharmacobiodyn 7:856-863.
25. Hodges GM, Carr EA, Hazzard RA, Carr KE. 1995. Uptake and translocation of microparticles in small intestine. Morphology and quantification of particle distribution. Dig Dis Sci 40(5):967-975.
26. Norris DA, Puri N, Sinko PJ. 1998. The effect of physical barriers and properties on the oral absorption of particulates. Adv Drug Deliv Rev 34:135-154.
27. Eldridge JH, Hammond CJ, Meulbroek HA. 1990. Controlled vaccine release in the gut-associated lymphoid tissues. I. Orally administered biodegradable microspheres target the Peyer's patches. J Controlled Release 11:205-214.